Patents Assigned to Eisai R&D Management Co., Ltd.
  • EP4 antagonists
    Patent number: 10941148
    Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: March 9, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Wanjun Zheng, Xiaojie Zhu, Hong Du, Maarten Postema, Yimin Jiang, Jing Li, Robert Yu, Hyeong-wook Choi, Jaemoon Lee, Frank Fang, Daniel Custar
  • Lysine conjugated immunoglobulins
    Patent number: 10941431
    Abstract: Provided herein are conjugated immunoglobulins and methods for generating conjugated immunoglobulins using a microbial transglutaminase.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: March 9, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Jared Spidel, Earl Albone
  • Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B
    Patent number: 10934307
    Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: March 2, 2021
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Francis G. Fang, Dae-Shik Kim, Hyeong-Wook Choi, Charles E. Chase, Jaemoon Lee
  • MONOCLONAL ANTIBODY AGAINST APOA4, IMMUNOLOGICAL MEASUREMENT METHOD, AND KIT FOR MEASUREMENT
    Publication number: 20210055300
    Abstract: The present invention provides an anti-APOA4 monoclonal antibody or an antibody fragment thereof capable of accurately measuring apolipoprotein A-IV (APOA4) in a specimen, a measurement method for immunologically measuring APOA4 using the antibody or the antibody fragment thereof, and a kit for measuring APOA4 containing the antibody or the antibody fragment thereof.
    Type: Application
    Filed: February 25, 2019
    Publication date: February 25, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yoko IDA, Takashi OBARA, Emiko YUMOTO
  • Pyrimidine FGFR4 inhibitors
    Patent number: 10912774
    Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: February 9, 2021
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Dominic Reynolds, Ming-Hong Hao, John Wang, Sudeep Prajapati, Takashi Satoh, Anand Selvaraj
  • Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides
    Patent number: 10913749
    Abstract: The invention provides methods for the synthesis of a halichondrin macrolides through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic macrolide. The invention also provides compounds useful as intermediates in the synthesis of a halichondrin macrolides and methods for preparing the same.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: February 9, 2021
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Francis G. Fang, Dae-Shik Kim, Hyeong-Wook Choi, Charles E. Chase
  • PHARMACEUTICAL COMPOSITION FOR TREATING TUMOR
    Publication number: 20210023047
    Abstract: Disclosed herein is a method for treating tumor, comprising administering a liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist to a patient in need thereof
    Type: Application
    Filed: March 31, 2020
    Publication date: January 28, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Taro Semba, Yasuhiro Funahashi
  • Liposome Composition
    Publication number: 20210023004
    Abstract: The present invention provides a novel liposome composition containing eribulin or its pharmacologically permissible salt, and its method of manufacture.
    Type: Application
    Filed: October 9, 2020
    Publication date: January 28, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Hiroshi KIKUCHI, Kenji HYODO, Hiroshi ISHIHARA
  • SALT OF PENTACYCLIC COMPOUND AND CRYSTAL THEREOF
    Publication number: 20210024541
    Abstract: Salts of the compound represented by formula (I) or crystals thereof have a potential use as drug substances for pharmaceuticals.
    Type: Application
    Filed: September 15, 2020
    Publication date: January 28, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Kenshi Yoshida, Yoshiaki Ohashi, Tamaki Hoshikawa, Nobuaki Sato, Ikuo Kushida
  • Splice variants associated with neomorphic SF3B1 mutants
    Patent number: 10889866
    Abstract: Splice variants associated with neomorphic SF3B1 mutations are described herein. This application also relates to methods of detecting the described splice variants, and uses for diagnosing cancer, evaluating modulators of SF3B1, and methods of treating cancer associated with mutations in SF3B1.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: January 12, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Lihua Yu, Kian Huat Lim, Jacob D. Feala, Silvia Buonamici, Yoshiharu Mizui, Peter G. Smith, Ping Zhu, Eunice Sun Park, Michael W. Seiler, Marco Peter Fekkes
  • EPILEPSY TREATMENT AGENT
    Publication number: 20210000771
    Abstract: Provided is a combination agent that combines N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide with an AMPA-type glutamate receptor antagonist such as 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one or 2-fluoro-6-(3-fluoro-8-oxo-7-(pyridin-3-yl)-7,8-dihydro-6H-pyrano[3,2-b:5,4-b?]dipyridin-9-yl)benzonitrile, and it has potential for use as a therapeutic agent for epilepsy.
    Type: Application
    Filed: March 18, 2019
    Publication date: January 7, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Hiroyuki Higashiyama, Hisashi Wakita, Yoshimasa Ito, Yoshihide OSADA
  • High-Purity Quinoline Derivative and Method for Manufacturing Same
    Publication number: 20200407322
    Abstract: Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less.
    Type: Application
    Filed: September 16, 2020
    Publication date: December 31, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Taiju Nakamura, Taichi Abe, Yusuke Miyashita, Hirofumi Kuroda, Yusuke Ayata, Atsushi Akao
  • Container
    Patent number: 10865011
    Abstract: Provided is a container including a main body, a lid body, and a fixing mechanism that fixes the lid body to prevent the lid body from opening from the main body when the lid body is closed, the fixing being released when the lid body moves to a front side with respect to the main body. Cutouts are formed in side plates of the main body. The container is configured such that, by a rear plate tilting forward toward the cutouts of the side plates, the lid body moves to the front side with respect to the main body and the fixing of the lid body is released, and as the rear plate and a top plate of the lid body form a single plane, the top plate rises and the lid body opens.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: December 15, 2020
    Assignee: Eisai R&D Management Co., Ltd.
    Inventor: Takahisa Sakaguchi
  • THERAPEUTIC AGENT FOR HEPATOCELLULAR CARCINOMA
    Publication number: 20200375970
    Abstract: Disclosed is a therapeutic agent for hepatocellular carcinoma, comprising 5-((2-(4-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: March 26, 2019
    Publication date: December 3, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Atsumi Yamaguchi, Hajime Shimizu, Satoshi Goda, Saori Miyano
  • Treatment of Renal Cell Carcinoma with Lenvatinib and Everolimus
    Publication number: 20200375975
    Abstract: Methods for treating a renal cell carcinoma with an improved combination of lenvatinib or a pharmaceutically acceptable salt thereof and everolimus are provided. These methods further comprises adjusting the dosages of lenvatinib during the onset of adverse effects to lead to improved treatment methods for human subjects with renal cell carcinoma. Particularly useful dosages and dose modifications upon the occurrence of adverse events are also provided.
    Type: Application
    Filed: August 19, 2020
    Publication date: December 3, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Alton KREMER, Corina DUTCUS
  • Tetrasubstituted alkene compounds and their use
    Patent number: 10851065
    Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: December 1, 2020
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Mark Bock, Ming-Hong Hao, Manav Korpal, Vijay Kumar Nyavanandi, Xiaoling Puyang, Susanta Samajdar, Peter Gerard Smith, John Wang, Guo Zhu Zheng, Ping Zhu
  • Combination Therapies for the Treatment of Hepatocellular Carcinoma
    Publication number: 20200360371
    Abstract: Provided herein is a combination therapy useful for the treatment hepatocellular carcinoma. The combination comprises an FGFR4 inhibitor and lenvatinib.
    Type: Application
    Filed: January 9, 2019
    Publication date: November 19, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Anand Selvaraj, Peter Smith
  • SOLID STATE FORM OF PLADIENOLIDE PYRIDINE COMPOUNDS AND METHODS OF USE
    Publication number: 20200361915
    Abstract: The present disclosure provides a novel solid state form of pladienolide pyridine compounds, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful.
    Type: Application
    Filed: July 17, 2020
    Publication date: November 19, 2020
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Parcharee Tivitmahaisoon, Sudeep Prajapati, Nicholas C. Gearhart, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai, Silvia Buonamici, Lihua Yu, Eunice Sun Park, Betty Chan, Peter G. Smith, Michael P. Thomas, Ermira Pazolli, Kian Huat Lim, Atsushi Endo, Arani Chanda
  • Substituted phosphorodiamidate morpholino oligomers
    Patent number: 10836784
    Abstract: A phosphoramidochloridate morpholino monomer of the following formula is provided:
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: November 17, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Atsushi Endo, Robert T. Yu, Francis Fang, Hyeong Wook Choi, Mingde Shan
  • COMBINATION COMPRISING AT LEAST ONE SPLICEOSOME MODULATOR AND AT LEAST ONE INHIBITOR CHOSEN FROM BCL2 INHIBITORS, BCL2/BCLXL INHIBITORS, AND BCLXL INHIBITORS AND METHODS OF USE
    Publication number: 20200352937
    Abstract: The present disclosure provides pharmaceutical combinations comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors. Also provided are methods of treating cancer comprising administering a therapeutically effective amount of at least one spliceosome modulator and a therapeutically effective amount of at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors.
    Type: Application
    Filed: October 30, 2018
    Publication date: November 12, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Daniel AIRD, Laura CORSON, Ping ZHU, Markus WARMUTH, Silvia BUONAMICI, Peter Gerard SMITH, Peter FEKKES